BioSpace News Archive

Halo Communications, a leading clinical communication and collaboration platform provider for health systems, announces the hiring of healthcare IT industry veteran, Kurt Hammond as Chief Growth Officer.

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 168,250 shares of Akebia’s common stock on January 31, 2020, as inducements material to each such employee’s entering into employment with Akebia.

Globe Life Inc. (NYSE: GL) reported today that for the quarter ended December 31, 2019, net income was $1.69 per diluted common share, compared with $1.45 per diluted common share for the year-ago quarter.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2019.

Globus Medical, Inc., a leading musculoskeletal solutions company announced Dr. Joshua S. Rovner became the first spine surgeon to implant HEDRON IA, a 3D printed integrated ALIF spacer that leverages anchors or screws for vertebral body fixation.

Afya Limited, or Afya, announced that it has launched a proposed follow-on public offering of 11,521,740 Class A common shares, consisting of 3,019,928 Class A common shares offered by Afya, and 8,501,812 Class A common shares offered by certain selling shareholders of Afya, including Crescera Educacional II Fundo de Investimento em Participações Multiestratégia, pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission.

Sage Therapeutics, Inc. announced that on Monday, February 3, 2020, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 13,950 shares of its common stock, and 6,325 performance restricted stock units to four new employees under Sage’s 2016 Inducement Equity Plan.

1Life Healthcare, Inc. announced the closing of its initial public offering of 20,125,000 shares of common stock at a price of $14.00 per share, which includes the full exercise of the underwriters’ option to purchase 2,625,000 additional shares of common stock.

Legends for Charity has raised nearly $8 million in 15 years for the lifesaving mission of St. Jude Children’s Research Hospital®.

United Therapeutics Corporation announced that on January 29, 2020, the United States District Court for the District of New Jersey issued a decision in favor of United Therapeutics and Smiths Medical ASD, Inc. denying the request for preliminary injunction sought by Sandoz Inc. and RareGen, LLC in pending antitrust litigation.